Esfahani, Mohammad S.
Lee, Luke J.
Jeon, Young-Jun
Flynn, Ryan A. http://orcid.org/0000-0001-5013-0442
Stehr, Henning
Hui, Angela B.
Ishisoko, Noriko
Kildebeck, Eric
Newman, Aaron M. http://orcid.org/0000-0002-1857-8172
Bratman, Scott V. http://orcid.org/0000-0001-8610-4908
Porteus, Matthew H. http://orcid.org/0000-0002-3850-4648
Chang, Howard Y. http://orcid.org/0000-0002-9459-4393
Alizadeh, Ash A. http://orcid.org/0000-0002-5153-5625
Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R25CA180993, R01CA188298, R01CA188298)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Ludwig Institute for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 8 November 2018
Accepted: 7 November 2019
First Online: 13 December 2019
Competing interests
: L.J.L. is an employee of and has ownership interests in 3 T Biosciences. N.I. is an employee of Genentech. A.M.N. is a co-inventor on patent applications related to ctDNA and other cancer biomarkers, has ownership interest in CiberMed, and has served as a consultant to CiberMed. S.V.B. is a co-inventor on patent applications related to cancer biomarkers. M.H.P. has ownership interests in and has served as a consultant for CRISPR Tx. H.Y.C. has ownership interests in Accent Therapeutics and has served as a consultant to 10X Genomics, Spring Discovery, and Accent Therapeutics. A.A.A. is a co-inventor on patent applications related to ctDNA and other cancer biomarkers, has ownership interests in CiberMed and FortySeven, and has served as a consultant/advisory board member for Genentech, Roche, Chugai, Gilead, Celgene, and CiberMed. M.D. is a co-inventor on patent applications related to ctDNA and other cancer biomarkers, has ownership interest in CiberMed, and has served as a consultant/advisory board member for Roche, AstraZeneca, Novartis, Quanticel, CiberMed, and BioNTech. All other authors have no conflicts of interest to declare.